IMMUNE NETWORK

  • 제22권5호
  • /
  • Pages.41.1-41.16
  • /
  • 2022
  • /
  • 1598-2629(pISSN)
  • /
  • 2092-6685(eISSN)
대한면역학회 (The Korean Association of Immunobiologists)
권호 표지
DOI QR코드

DOI QR Code

Application of Antimicrobial Peptide LL-37 as an Adjuvant for Middle East Respiratory Syndrome-Coronavirus Antigen Induces an Efficient Protective Immune Response Against Viral Infection After Intranasal Immunization

  • Ju Kim (Department of Molecular Biology and the Institute for Molecular Biology and Genetics, Jeonbuk National University) ;
  • Ye Lin Yang (Department of Bioactive Material Sciences and Research Center of Bioactive Materials, Jeonbuk National University) ;
  • Yongsu Jeong (Graduate School of Biotechnology, Kyung Hee University) ;
  • Yong-Suk Jang (Department of Molecular Biology and the Institute for Molecular Biology and Genetics, Jeonbuk National University)
  • 투고 : 2022.04.09
  • 심사 : 2022.08.22
  • 발행 : 2022.10.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The human antimicrobial peptide LL-37 has chemotactic and modulatory activities in various immune cells, including dendritic cells. Because of its characteristics, LL-37 can be considered an adjuvant for vaccine development. In this study, we confirmed the possible adjuvant activity of LL-37 in mucosal vaccine development against Middle East respiratory syndrome-coronavirus (MERS-CoV) by means of intranasal immunization in C57BL/6 and human dipeptidyl peptidase 4 (hDPP4)-transgenic (hDPP4-Tg) mice. Intranasal immunization using the receptor-binding domain (RBD) of MERS-CoV spike protein (S-RBD) recombined with LL-37 (S-RBD-LL-37) induced an efficient mucosal IgA and systemic IgG response with virus-neutralizing activity, compared with S-RBD. Ag-specific CTL stimulation was also efficiently induced in the lungs of mice that had been intranasally immunized with S-RBD-LL-37, compared with S-RBD. Importantly, intranasal immunization of hDPP4-Tg mice with S-RBD-LL-37 led to reduced immune cell infiltration into the lungs after infection with MERS-CoV. Finally, intranasal immunization of hDPP4-Tg mice with S-RBD-LL-37 led to enhanced protective efficacy, with increased survival and reduced body weight loss after challenge infection with MERS-CoV. Collectively, these results suggest that S-RBD-LL-37 is an effective intranasal vaccine candidate molecule against MERS-CoV infection.

키워드

과제정보

This work was supported by grants from the Basic Science Research Program (2019R1A2C2004711) through the National Research Foundation, which is funded by the Korean Ministry of Science and ICT, and the Basic Science Research Program through the NRF, which is funded by the Ministry of Education (2017R1A6A1A03015876). Y. L. Yang was supported by the BK21 FOUR program in the Department of Bioactive Material Sciences. Some experiments were performed using instruments installed in the Center for University-Wide Research Facilities (CURF) at Jeonbuk National University.

참고문헌

  1. Yang B, Good D, Mosaiab T, Liu W, Ni G, Kaur J, Liu X, Jessop C, Yang L, Fadhil R, et al. Significance of LL-37 on immunomodulation and disease outcome. BioMed Res Int 2020;2020:8349712.
  2. Pace BT, Lackner AA, Porter E, Pahar B. The role of defensins in HIV pathogenesis. Mediators Inflamm 2017;2017:5186904.
  3. Doss M, White MR, Tecle T, Hartshorn KL. Human defensins and LL-37 in mucosal immunity. J Leukoc Biol 2010;87:79-92. https://doi.org/10.1189/jlb.0609382
  4. Kim SH, Yang IY, Kim J, Lee KY, Jang YS. Antimicrobial peptide LL-37 promotes antigen-specific immune responses in mice by enhancing Th17-skewed mucosal and systemic immunities. Eur J Immunol 2015;45:1402-1413. https://doi.org/10.1002/eji.201444988
  5. Seil M, Nagant C, Dehaye JP, Vandenbranden M, Lensink MF. Spotlight on human LL-37, an immunomodulatory peptide with promising cell-penetrating properties. Pharmaceuticals (Basel) 2010;3:3435-3460. https://doi.org/10.3390/ph3113435
  6. Nijnik A, Pistolic J, Wyatt A, Tam S, Hancock RE. Human cathelicidin peptide LL-37 modulates the effects of IFN-γ on APCs. J Immunol 2009;183:5788-5798. https://doi.org/10.4049/jimmunol.0901491
  7. Reinholz M, Ruzicka T, Schauber J. Cathelicidin LL-37: an antimicrobial peptide with a role in inflammatory skin disease. Ann Dermatol 2012;24:126-135. https://doi.org/10.5021/ad.2012.24.2.126
  8. Kim SH, Jang YS. Antigen targeting to M cells for enhancing the efficacy of mucosal vaccines. Exp Mol Med 2014;46:e85.
  9. Alpar HO, Bramwell VW. Current status of DNA vaccines and their route of administration. Crit Rev Ther Drug Carrier Syst 2002;19:307-383. https://doi.org/10.1615/CritRevTherDrugCarrierSyst.v19.i45.20
  10. Fiore AE, Bridges CB, Cox NJ. Seasonal influenza vaccines. Curr Top Microbiol Immunol 2009;333:43-82. https://doi.org/10.1007/978-3-540-92165-3_3
  11. Childers NK, Li F, Dasanayake AP, Li Y, Kirk K, Michalek SM. Immune response in humans to a nasal boost with Streptococcus mutans antigens. Oral Microbiol Immunol 2006;21:309-313. https://doi.org/10.1111/j.1399-302X.2006.00302.x
  12. Kim SH, Jang YS. Recent Insights into cellular crosstalk in respiratory and gastrointestinal mucosal immune systems. Immune Netw 2020;20:e44.
  13. Memish ZA, Perlman S, Van Kerkhove MD, Zumla A. Middle East respiratory syndrome. Lancet 2020;395:1063-1077. https://doi.org/10.1016/S0140-6736(19)33221-0
  14. Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet 2015;386:995-1007. https://doi.org/10.1016/S0140-6736(15)60454-8
  15. Gierer S, Bertram S, Kaup F, Wrensch F, Heurich A, Kramer-Kuhl A, Welsch K, Winkler M, Meyer B, Drosten C, et al. The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies. J Virol 2013;87:5502-5511. https://doi.org/10.1128/JVI.00128-13
  16. Raj VS, Mou H, Smits SL, Dekkers DH, Muller MA, Dijkman R, Muth D, Demmers JA, Zaki A, Fouchier RA, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013;495:251-254. https://doi.org/10.1038/nature12005
  17. Tai W, Zhao G, Sun S, Guo Y, Wang Y, Tao X, Tseng CK, Li F, Jiang S, Du L, et al. A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection. Virology 2016;499:375-382. https://doi.org/10.1016/j.virol.2016.10.005
  18. Kathiravan MK, Radhakrishnan S, Namasivayam V, Palaniappan S. An overview of spike surface glycoprotein in severe acute respiratory syndrome-coronavirus. Front Mol Biosci 2021;8:637550.
  19. Kim J, Yang YL, Jeong Y, Jang YS. Middle East respiratory syndrome-coronavirus infection into established hDPP4-transgenic mice accelerates lung damage via activation of the pro-inflammatory response and pulmonary fibrosis. J Microbiol Biotechnol 2020;30:427-438. https://doi.org/10.4014/jmb.1910.10055
  20. Ma C, Wang L, Tao X, Zhang N, Yang Y, Tseng CK, Li F, Zhou Y, Jiang S, Du L. Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments--the importance of immunofocusing in subunit vaccine design. Vaccine 2014;32:6170-6176. https://doi.org/10.1016/j.vaccine.2014.08.086
  21. Kim J, Yang YL, Jeong Y, Jang YS. Conjugation of human β-defensin 2 to spike protein receptor-binding domain induces antigen-specific protective immunity against Middle East respiratory syndrome-coronavirus infection in human dipeptidyl peptidase 4 transgenic mice. Vaccines (Basel) 2020;8:635.
  22. McGhee JR, Fujihashi K. Inside the mucosal immune system. PLoS Biol 2012;10:e1001397.
  23. Kiyono H, Fukuyama S. NALT- versus Peyer's-patch-mediated mucosal immunity. Nat Rev Immunol 2004;4:699-710. https://doi.org/10.1038/nri1439
  24. Harty JT, Tvinnereim AR, White DW. CD8+ T cell effector mechanisms in resistance to infection. Annu Rev Immunol 2000;18:275-308. https://doi.org/10.1146/annurev.immunol.18.1.275
  25. Williamson JS, Stohlman SA. Effective clearance of mouse hepatitis virus from the central nervous system requires both CD4+ and CD8+ T cells. J Virol 1990;64:4589-4592. https://doi.org/10.1128/jvi.64.9.4589-4592.1990
  26. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M, Koup RA. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003;281:65-78. https://doi.org/10.1016/S0022-1759(03)00265-5
  27. Takeuchi A, Saito T. CD4 CTL, a cytotoxic subset of CD4+ T cells, their differentiation and function. Front Immunol 2017;8:194.
  28. van Leeuwen EM, Remmerswaal EB, Vossen MT, Rowshani AT, Wertheim-van Dillen PM, van Lier RA, ten Berge IJ. Emergence of a CD4+CD28-  granzyme B+, cytomegalovirus-specific T cell subset after recovery of primary cytomegalovirus infection. J Immunol 2004;173:1834-1841. https://doi.org/10.4049/jimmunol.173.3.1834
  29. Pahar B, Madonna S, Das A, Albanesi C, Girolomoni G. Immunomodulatory role of the antimicrobial LL37 peptide in autoimmune diseases and viral infections. Vaccines (Basel) 2020;8:517.
  30. Currie SM, Gwyer Findlay E, McFarlane AJ, Fitch PM, Bottcher B, Colegrave N, Paras A, Jozwik A, Chiu C, Schwarze J, et al. Cathelicidins have direct antiviral activity against respiratory syncytial virus in vitro and protective function in vivo in mice and humans. J Immunol 2016;196:2699-2710. https://doi.org/10.4049/jimmunol.1502478
  31. Alagarasu K, Patil PS, Shil P, Seervi M, Kakade MB, Tillu H, Salunke A. In-vitro effect of human cathelicidin antimicrobial peptide LL-37 on dengue virus type 2. Peptides 2017;92:23-30. https://doi.org/10.1016/j.peptides.2017.04.002
  32. He M, Zhang H, Li Y, Wang G, Tang B, Zhao J, Huang Y, Zheng J. Cathelicidin-derived antimicrobial peptides inhibit zika virus through direct inactivation and interferon pathway. Front Immunol 2018;9:722.
  33. Yu Y, Cooper CL, Wang G, Morwitzer MJ, Kota K, Tran JP, Bradfute SB, Liu Y, Shao J, Zhang AK, et al. Engineered human cathelicidin antimicrobial peptides inhibit Ebola virus infection. iScience 2020;23:100999.
  34. Guthrie BL, Introini A, Roxby AC, Choi RY, Bosire R, Lohman-Payne B, Hirbod T, Farquhar C, Broliden K. Depot medroxyprogesterone acetate (DMPA) use is associated with elevated innate immune effector molecules in cervicovaginal secretions of HIV-1-uninfected women. J Acquir Immune Defic Syndr 2015;69:1-10. https://doi.org/10.1097/QAI.0000000000000533
  35. Sousa FH, Casanova V, Findlay F, Stevens C, Svoboda P, Pohl J, Proudfoot L, Barlow PG. Cathelicidins display conserved direct antiviral activity towards rhinovirus. Peptides 2017;95:76-83. https://doi.org/10.1016/j.peptides.2017.07.013
  36. Agerberth B, Charo J, Werr J, Olsson B, Idali F, Lindbom L, Kiessling R, Jornvall H, Wigzell H, Gudmundsson GH. The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. Blood 2000;96:3086-3093. https://doi.org/10.1182/blood.V96.9.3086
  37. De Yang , Chen Q, Schmidt AP, Anderson GM, Wang JM, Wooters J, Oppenheim JJ, Chertov O. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med 2000;192:1069-1074. https://doi.org/10.1084/jem.192.7.1069
  38. Muniz LR, Knosp C, Yeretssian G. Intestinal antimicrobial peptides during homeostasis, infection, and disease. Front Immunol 2012;3:310.
  39. Kim SH, Kim YN, Jang YS. Cutting edge: LL-37-mediated formyl peptide receptor-2 signaling in follicular dendritic cells contributes to B cell activation in Peyer's patch germinal centers. J Immunol 2017;198:629-633. https://doi.org/10.4049/jimmunol.1600886
  40. Ogra PL, Faden H, Welliver RC. Vaccination strategies for mucosal immune responses. Clin Microbiol Rev 2001;14:430-445. https://doi.org/10.1128/CMR.14.2.430-445.2001
  41. Alu A, Chen L, Lei H, Wei Y, Tian X, Wei X. Intranasal COVID-19 vaccines: from bench to bed. EBioMedicine 2022;76:103841.
  42. Kurosaki T, Katafuchi Y, Hashizume J, Harasawa H, Nakagawa H, Nakashima M, Nakamura T, Yamashita C, Sasaki H, Kodama Y. Induction of mucosal immunity by pulmonary administration of a cell-targeting nanoparticle. Drug Deliv 2021;28:1585-1593. https://doi.org/10.1080/10717544.2021.1955040
  43. Molaei S, Dadkhah M, Asghariazar V, Karami C, Safarzadeh E. The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: vaccine design strategies. Int Immunopharmacol 2021;92:107051.
  44. Allen T, Murray KA, Zambrana-Torrelio C, Morse SS, Rondinini C, Di Marco M, Breit N, Olival KJ, Daszak P. Global hotspots and correlates of emerging zoonotic diseases. Nat Commun 2017;8:1124.
  45. Barlan A, Zhao J, Sarkar MK, Li K, McCray PB Jr, Perlman S, Gallagher T. Receptor variation and susceptibility to Middle East respiratory syndrome coronavirus infection. J Virol 2014;88:4953-4961. https://doi.org/10.1128/JVI.00161-14
  46. Nassar MS, Bakhrebah MA, Meo SA, Alsuabeyl MS, Zaher WA. Middle East respiratory syndrome coronavirus (MERS-CoV) infection: epidemiology, pathogenesis and clinical characteristics. Eur Rev Med Pharmacol Sci 2018;22:4956-4961.
  47. Seo KW, Kim SH, Park J, Son Y, Yoo HS, Lee KY, Jang YS. Nasal immunization with major epitope-containing ApxIIA toxin fragment induces protective immunity against challenge infection with Actinobacillus pleuropneumoniae in a murine model. Vet Immunol Immunopathol 2013;151:102-112. https://doi.org/10.1016/j.vetimm.2012.10.011
  48. Hassan AO, Shrihari S, Gorman MJ, Ying B, Yaun D, Raju S, Chen RE, Dmitriev IP, Kashentseva E, Adams LJ, et al. An intranasal vaccine durably protects against SARS-CoV-2 variants in mice. Cell Reports 2021;36:109452.
  49. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005;11:S45-S53. https://doi.org/10.1038/nm1213
  50. van Doremalen N, Miazgowicz KL, Milne-Price S, Bushmaker T, Robertson S, Scott D, Kinne J, McLellan JS, Zhu J, Munster VJ. Host species restriction of Middle East respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4. J Virol 2014;88:9220-9232. https://doi.org/10.1128/JVI.00676-14
  51. Nierkens S, Tel J, Janssen E, Adema GJ. Antigen cross-presentation by dendritic cell subsets: one general or all sergeants? Trends Immunol 2013;34:361-370. https://doi.org/10.1016/j.it.2013.02.007
  52. Ballesteros-Tato A, Leon B, Lund FE, Randall TD. Temporal changes in dendritic cell subsets, cross-priming and costimulation via CD70 control CD8+ T cell responses to influenza. Nat Immunol 2010;11:216-224. https://doi.org/10.1038/ni.1838
  53. Davidson DJ, Currie AJ, Reid GS, Bowdish DM, MacDonald KL, Ma RC, Hancock RE, Speert DP. The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. J Immunol 2004;172:1146-1156. https://doi.org/10.4049/jimmunol.172.2.1146
  54. Zhao J, Li K, Wohlford-Lenane C, Agnihothram SS, Fett C, Zhao J, Gale MJ Jr, Baric RS, Enjuanes L, Gallagher T, et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci U S A 2014;111:4970-4975. https://doi.org/10.1073/pnas.1323279111
  55. Wei HX, Wang B, Li B. IL-10 and IL-22 in mucosal immunity: driving protection and pathology. Front Immunol 2020;11:1315.
  56. Lee P, Kim DJ. Newly emerging human coronaviruses: animal models and vaccine research for SARS, MERS, and COVID-19. Immune Netw 2020;20:e28.
  57. Ohnuma K, Dang NH, Morimoto C. Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function. Trends Immunol 2008;29:295-301. https://doi.org/10.1016/j.it.2008.02.010